Wilsons Equity Research has released an updated analysis on Hexima Limited, with a view on the potential for success in phase II. Wilsons maintains...
Wilsons Updated Research Report
read more
Company News
Presentation at American Academy of Dermatology March 2022
Pezadeftide Mode of Action Hexima is proud to present new data describing the unique mechanism of action of pezadeftide as a potent antifungal...
Wilsons Research Report
Recently WILSONS published its initiation research report on Hexima Limited (ASX:HXL) with an OVERWEIGHT rating and a $0.75 12-month price target....
Phil Rose appointed Chief Commercial Officer
Hexima announces the appointment of Phillip Rose as Chief Commercial Officer, based in the U.S. Phillip Rose reports to Michael Aldridge, Managing...
Nancy Sacco appointed Chief Development Officer
Hexima announces the appointment of Dr Nancy Sacco, PhD as Chief Development Officer. Dr Sacco will report to Michael Aldridge, Managing Director...
Completion of $10 Million Institutional Placement
Hexima is pleased to announce that it has completed the bookbuild for a placement to raise $10.0 million. In addition, Hexima proposes to launch a...
Review of FY21 – Investor Webinar
Watch Hexima's CEO, Mr Michael Aldridge, review the achievements of FY21 and inform investors of expected important developments and milestones....